Femoral or Radial Secondary Access in TAVR: A Subanalysis From the Multicenter PULSE Registry: @JACCJournals
🥸So we tried to use #radialfirst in TAVR like the old days, but we were shot by anesthesia!
😱Summary
👇👇👇
Merry Xmas! The team of Urology, @uni-freiburg.de, would like to thank all our co-workers and cooperation partners for the support in 2024. And to all patients: please go see a Urologist if needed! We are here for you…
"#HscTnI is a known marker of CV risk, but what about changes 🔃 over time? New study by @PaulMHaller and @marstonMD using >20k pts from FOURIER trial explores how serial increases & decreases in hs-cTnI reflect shifts⤴️/⤵️ in risk of major CV event risk. #CardioTwitter#AHA24"
Microaxial Flow Pump Hemodynamic and Metabolic Effects in Infarct-Related Cardiogenic Shock: A Substudy of the DanGer Shock Randomized Clinical Trial | Critical Care Medicine | JAMA Cardiology | JAMA Network - lmpella patients need less inotropes… https://t.co/rNovaSa6We
Ouch, QFR. In the FAVOR III Europe trial, it loses out against FFR for PCI guidance. For those who enjoy statistical tortures, QFR didn’t just fail to show noninferiority; it was actually inferior. More stents, more myocardial infarctions. Who will give me back the hours I spent obtaining the certification? #TCT2024 https://t.co/tq8cOVf6MF
Always the biggest most exciting meeting of the year #TCT2024 Check out an amazing session on CS & MCS led by @alaide_chief & @dirkwestermann at 10:30, including 3 analyses from Danger Shock @LHolmvang@djc795 & the first look into the future of small bore MCS @DrAmirKaki
In 32,000 AF pts from COMBINE-AF, cardiac #biomarkers sign.⤴️ #heartfailure risk prediction! hs-cTnT as important as NTproBNP pointing to a promising dual-marker strategy. Results simultaneously published in @JACCJournals @PaulMHaller @rgiugliano#ESCCongress
Congratulations to @thiele_holger on the recently published independent patient data meta-analysis evaluating whether VA ECMO benefit DanGer-like patients.
https://t.co/aQdo8a1r3x